VivoSeq
Oncology

Mesothelioma

77

Pipeline Programs↗

12

Active Trials↗

38

Companies Involved↗

Mesothelioma is a moderately active landscape with 77 programs across 38 companies. The most active players are EMD Serono, Exela Pharma Sciences, LLC., Essen Biotech. 12 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

11/100

Mech. Concentration

5/100

Completion Rate

69/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1E

Exela Pharma Sciences, LLC.

1 program

Phase 1E

Essen Biotech

1 program

Phase 1H

Hope Pharmaceuticals

1 program

Phase 1C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 1S

Selecta Biosciences, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical3

Nivolumab

Bristol-Myers Squibb

TC-510

TCR2 Therapeutics

PTC Guided Individualized Treatment

Beijing Tsinghua Chang Gung Hospital

Phase 119

Avelumab

EMD Serono

Cyclophosphamide

Baxter Healthcare Corporation

Ganciclovir

Exela Pharma Sciences, LLC.

Doxorubicin

Pfizer

Fludarabine

Sanofi

Phase 232

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Antineoplaston A10

Burzynski Research Institute

Vinorelbine

Pierre Fabre Medicament

Cediranib Maleate

National Cancer Institute (NCI)

Cixutumumab

Eli Lilly

Phase 311

Pemetrexed Disodium

Gynecologic Oncology Group

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Anetumab Ravtansine

Bayer

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Ipilimumab

Bristol-Myers Squibb

Approved12

TAZEMETOSTAT

Epizyme, Inc.

Belinostat

Acrotech Biopharma Inc.

Olaparib

AstraZeneca

Trabectedin

Apotex Inc.

Porfimer Sodium

Pinnacle Biologics Inc.

Analysis

Modality Breakdown

75%

Small molecule

57 of 76 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody1317%Protein / enzyme34%Cell therapy23%Vaccine11%

Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 100% of 87 pipeline programs.

Analysis

Trial Status

49

clinical trials

Completed22 · 45%
Terminated8 · 16%
Active, not recruiting6 · 12%
Recruiting6 · 12%
Unknown status5 · 10%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

49 trials

dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
Recruiting·EErasmus Medical Center·Phase 1·NCT05304208·16 enrolled
PTC-Guided Therapy for Peritoneal Mesothelioma
Recruiting·—·N/A·NCT07330271·347 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06885697·100 enrolled
A Study of Sacituzumab Govitecan in People With Mesothelioma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06477419·33 enrolled
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Recruiting·—·Phase 1/2·NCT05932199·52 enrolled
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
Recruiting·National Cancer Institute (NCI)·N/A·NCT03830229·1,000 enrolled
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04577326·14 enrolled
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04162015·22 enrolled
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04897022·7 enrolled
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT02535312·30 enrolled
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Active, not recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 1·NCT03546426·18 enrolled
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Active, not recruiting·Novartis logoNovartis·Phase 1·NCT04857372·137 enrolled
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Completed·—·Phase 2·NCT00137826·37 enrolled
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Completed·UUniversity Hospital Southampton NHS Foundation Trust·Phase 2·NCT05455424·88 enrolled
Vinorelbine in Mesothelioma
Completed·WWales Cancer Trials Unit·Phase 2·NCT02139904·154 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)